Organization Jan 20, 2023 Astellas' Zolbetuximab Plus Chemo Benefits CLDN18.2-Positive, HER2-Negative Gastric Cancer Patients Premium Jan 20, 2023 Mirati Therapeutics' KRAS G12D Inhibitor Cleared by FDA to Begin Phase I/II Trial Jan 19, 2023 Colorectal Cancer Detection Data from CellMax Life Bodes Well for Planned FDA Bid Premium Jan 19, 2023 Liquid Biopsy Biomarker Score Predicts Relapse in Lymphoma Patients After CAR T-Cell Treatment Premium Jan 19, 2023 Guardant Health, Royal Marsden Partner on Prospective Liquid Biopsy Trial in Early Colorectal Cancer Jan 18, 2023 Penn Scientists Testing Out CAR T-Cell Therapy Gel to Prevent Breast Cancer Recurrence Post-Surgery Premium Jan 18, 2023 Freenome Partners With Geisinger to Recruit Patients for Multi-Cancer Screening Study Jan 18, 2023 Genetron Regains Compliance With Nasdaq Listing Requirement Jan 17, 2023 Inflammatory Gene Expression Score IDs High-Risk AML Patients Premium Jan 11, 2023 Texas Research Institute, TGen, OncoHost Partner to ID Lung Cancer Resistance Mechanisms Jan 10, 2023 Immunocore Unveils New T-Cell Receptor Therapy Candidates, Estimates $140M in 2022 Kimmtrak Sales Jan 10, 2023 Could PD-L1/2 Structural Variants be the Next Pan-Cancer Predictive Immunotherapy Biomarker? Premium Jan 10, 2023 Sophia Genetics to Commercialize MSK-ACCESS Clinical Liquid Biopsy Test Jan 10, 2023 Prenetics' ACT Genomics Profiling Test for Solid Tumors Receives FDA Clearance Jan 9, 2023 Aethon Therapeutics Launches With $30M in Series A Funding to Tackle Cancer Therapy Resistance Jan 6, 2023 BioNTech, UK Government to Expand Access to Personalized mRNA Cancer Vaccines in England Jan 6, 2023 Immune Signatures Outperform TILs for HER2-Positive Breast Cancer Prognoses Jan 5, 2023 Pharmacotyping Links Childhood Leukemia Subtypes to Treatment Response Jan 4, 2023 FDA Approves Foundation Medicine Blood Test as CDx for Rozlytrek Jan 4, 2023 Precision Oncology in 2022: New Drugs and Tests Amid Ongoing Access Barriers Premium Load More Breaking News Marengo Therapeutics Begins Phase I/II Trial of Selective T-Cell-Targeted Antibody Janssen, Legend Biotech's Carvykti Bests Chemo in Earlier-Line Multiple Myeloma Trial In Brief This Week: PreludeDx, Johnson & Johnson, Syros, Magenta, Merck NICE Backs Gilead Sciences' Yescarta as Third-Line Option for Lymphoma Patients BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer
